Table 1 Patients, tumours, and treatment characteristics, by cohort (cohort A, n=35, no trastuzumab; cohort B, n=53, adjuvant trastuzumab only; cohort C, n=199, both neadjuvant and adjuvant trastuzumab)
Whole population ( n =287) | Cohort A ( n =35), no trastuzumab | Cohort B ( n =53), adjuvant tz* only | Cohort C ( n =199), neoadjuvant and adjuvant tz* | ||||||
|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | P -value | |
Time period | |||||||||
2002–2005 | 70 | 24.4% | 34 | 97.1% | 25 | 47.2% | 11 | 5.5% | <0.01 |
2006–2011 | 217 | 75.6% | 1 | 2.9% | 28 | 52.8% | 188 | 94.5% | |
Age | |||||||||
<45 y.o. | 115 | 40.1% | 12 | 34.3% | 24 | 45.3% | 79 | 39.7% | 0.70 |
45–55 y.o | 94 | 32.8% | 11 | 31.4% | 18 | 34.0% | 65 | 32.7% | |
>55 y.o. | 78 | 27.2% | 12 | 34.3% | 11 | 20.8% | 55 | 27.6% | |
Menopausal status | |||||||||
Premenopausal | 176 | 61.3% | 20 | 57.1% | 36 | 67.9% | 120 | 60.3% | 0.42 |
Postmenopausal | 110 | 38.3% | 15 | 42.9% | 16 | 30.2% | 79 | 39.7% | |
T stage | |||||||||
T1 | 18 | 6.3% | 3 | 8.6% | 2 | 3.8% | 13 | 6.5% | 0.89 |
T2 | 193 | 67.2% | 24 | 68.6% | 35 | 66.0% | 134 | 67.3% | |
T3 | 75 | 26.1% | 8 | 22.9% | 15 | 28.3% | 52 | 26.1% | |
N stage | |||||||||
N0 | 118 | 41.1% | 20 | 57.1% | 17 | 32.1% | 81 | 40.7% | 0.06 |
N1, N2, N3 | 169 | 58.9% | 15 | 42.9% | 36 | 67.9% | 118 | 59.3% | |
BMI | |||||||||
BMI⩽30 | 253 | 88.2% | 31 | 88.6% | 49 | 92.5% | 173 | 86.9% | 0.59 |
BMI>30 | 33 | 11.5% | 4 | 11.4% | 4 | 7.5% | 25 | 12.6% | |
Histological type | |||||||||
Ductal | 271 | 94.4% | 29 | 82.9% | 50 | 94.3% | 192 | 96.5% | 0.84 |
Others | 7 | 2.4% | 1 | 2.9% | 1 | 1.9% | 5 | 2.5% | |
Grade (EE) | |||||||||
Grade I | 2 | 0.7% | 1 | 2.9% | 0 | 0.0% | 1 | 0.5% | 0.23 |
Grade II | 93 | 32.4% | 12 | 34.3% | 20 | 37.7% | 61 | 30.7% | |
Grade III | 179 | 62.4% | 17 | 48.6% | 29 | 54.7% | 133 | 66.8% | |
Hormone receptor (HR) | |||||||||
Positive | 157 | 54.7% | 18 | 51.4% | 28 | 52.8% | 111 | 55.8% | 0.88 |
Negative | 129 | 44.9% | 17 | 48.6% | 24 | 45.3% | 88 | 44.2% | |
Oestrogen receptor (ER) | |||||||||
Negative | 138 | 48.1% | 17 | 48.6% | 27 | 50.9% | 94 | 47.2% | 0.89 |
Positive | 149 | 51.9% | 18 | 51.4% | 26 | 49.1% | 105 | 52.8% | |
Progesterone receptor (PR) | |||||||||
Negative | 183 | 63.8% | 25 | 71.4% | 33 | 62.3% | 125 | 62.8% | 0.51 |
Positive | 100 | 34.8% | 9 | 25.7% | 19 | 35.8% | 72 | 36.2% | |
Surgery | |||||||||
Lumpectomy | 199 | 69.3% | 26 | 74.3% | 34 | 64.2% | 139 | 69.8% | 0.61 |
Mastectomy | 88 | 30.7% | 9 | 25.7% | 19 | 35.8% | 60 | 30.2% | |
Sentinel node Biopsy | 8 | 2.8% | 0 | 0.0% | 0 | 0.0% | 8 | 4.0% | 0.32 |
Axillary node dissection | 279 | 97.2% | 35 | 100.0% | 53 | 100.0% | 191 | 96.0% | |
Number of nodes involved | |||||||||
None | 200 | 69.7% | 21 | 60.0% | 25 | 47.2% | 154 | 77.4% | <0.01 |
1–3 | 67 | 23.3% | 11 | 31.4% | 21 | 39.6% | 35 | 17.6% | |
⩾4 | 20 | 7.0% | 3 | 8.6% | 7 | 13.2% | 10 | 5.0% | |
Strict pCR | |||||||||
No | 211 | 73.5% | 29 | 82.9% | 49 | 92.5% | 133 | 66.8% | <0.01 |
Yes | 76 | 26.5% | 6 | 17.1% | 4 | 7.5% | 66 | 33.2% | |
pCR | |||||||||
No | 175 | 61.0% | 26 | 74.3% | 45 | 84.9% | 104 | 52.3% | <0.01 |
Yes | 112 | 39.0% | 9 | 25.7% | 8 | 15.1% | 95 | 47.7% | |
Adjuvant chemotherapy | |||||||||
No | 254 | 88.5% | 33 | 94.3% | 37 | 69.8% | 184 | 92.5% | <0.01 |
Yes | 33 | 11.5% | 2 | 5.7% | 16 | 30.2% | 15 | 7.5% | |
Trastuzumab | |||||||||
No | 35 | 12.2% | 35 | 100.0% | 0 | 0.0% | 0 | 0.0% | |
Adjuvant only | 53 | 18.5% | 0 | 0.0% | 53 | 100.0% | 0 | 0.0% | |
Neoadjuvant and adjuvant | 199 | 69.3% | 0 | 0.0% | 0 | 0.0% | 199 | 100.0% | |
Endocrine therapy | |||||||||
No | 150 | 52.3% | 19 | 54.3% | 32 | 60.4% | 99 | 49.7% | 0.38 |
Yes | 137 | 47.7% | 16 | 45.7% | 21 | 39.6% | 100 | 50.3% | |
Tamoxifen | 65 | 22.6% | 14 | 40.0% | 7 | 13.2% | 44 | 22.1% | |
Aromatase inhibitor | 50 | 17.4% | 1 | 2.9% | 5 | 9.4% | 44 | 22.1% | |
Others | 22 | 7.7% | 1 | 2.9% | 9 | 17.0% | 12 | 6.0% | |
Follow-up | |||||||||
Median (range) | 46 | (6–122) | 96 | (40–122) | 67 | (25–95) | 33 | (6–92) | <0.01 |
